PENGO, VITTORIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 20.518
AS - Asia 2.896
EU - Europa 2.543
SA - Sud America 149
AF - Africa 38
Continente sconosciuto - Info sul continente non disponibili 10
OC - Oceania 8
Totale 26.162
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 20.485
SG - Singapore 1.347
CN - Cina 1.136
FI - Finlandia 491
DE - Germania 462
SE - Svezia 343
UA - Ucraina 297
IT - Italia 275
VN - Vietnam 226
GB - Regno Unito 200
FR - Francia 189
RU - Federazione Russa 166
BR - Brasile 131
HK - Hong Kong 95
NL - Olanda 45
CI - Costa d'Avorio 33
IN - India 27
IE - Irlanda 21
CA - Canada 19
AT - Austria 15
JP - Giappone 13
KR - Corea 13
BE - Belgio 12
EU - Europa 10
TR - Turchia 8
MX - Messico 7
VE - Venezuela 7
CZ - Repubblica Ceca 6
IQ - Iraq 6
GR - Grecia 5
AE - Emirati Arabi Uniti 4
AU - Australia 4
BD - Bangladesh 4
NZ - Nuova Zelanda 4
AR - Argentina 3
ES - Italia 3
HU - Ungheria 3
LT - Lituania 3
NP - Nepal 3
UZ - Uzbekistan 3
CH - Svizzera 2
CO - Colombia 2
EC - Ecuador 2
EG - Egitto 2
GT - Guatemala 2
JO - Giordania 2
KZ - Kazakistan 2
MA - Marocco 2
PY - Paraguay 2
RO - Romania 2
BG - Bulgaria 1
CL - Cile 1
CR - Costa Rica 1
HN - Honduras 1
IR - Iran 1
JM - Giamaica 1
KW - Kuwait 1
LK - Sri Lanka 1
LV - Lettonia 1
PA - Panama 1
PE - Perù 1
PK - Pakistan 1
PR - Porto Rico 1
PS - Palestinian Territory 1
PT - Portogallo 1
TH - Thailandia 1
TN - Tunisia 1
TW - Taiwan 1
Totale 26.162
Salva come PNG Salva come JPEG
Città #
Fairfield 3.552
Woodbridge 2.049
Houston 1.479
Ashburn 1.422
Chandler 1.357
Jacksonville 1.344
Cambridge 1.226
Seattle 1.221
Ann Arbor 1.205
Wilmington 1.193
Singapore 599
Princeton 562
Boardman 506
San Diego 366
Beijing 243
Santa Clara 229
Dong Ket 226
Nanjing 212
Medford 204
Roxbury 193
Des Moines 191
Helsinki 177
Guangzhou 109
Hong Kong 95
Padova 85
Hebei 60
London 59
Nanchang 59
Shenyang 58
Norwalk 47
Jiaxing 42
New York 39
Abidjan 33
Redwood City 33
Changsha 32
Frankfurt am Main 32
Jinan 31
Falls Church 29
Ogden 27
Tianjin 25
Hefei 24
Dublin 19
Tappahannock 18
Kharkiv 17
Shanghai 17
Indiana 16
Falkenstein 15
Kunming 15
Zhengzhou 14
Chicago 13
Milan 13
Nuremberg 13
Rome 13
Dearborn 11
Ningbo 11
Seoul 11
Brussels 10
Detroit 10
Munich 10
Washington 10
Kilburn 9
Mestre 9
Redmond 9
Borås 7
Los Angeles 7
Nürnberg 7
Chiswick 6
Lanzhou 6
Orange 6
Prescot 6
Pune 6
Rockville 6
São Paulo 6
Tokyo 6
Campinas 5
Groningen 5
Rio de Janeiro 5
Taiyuan 5
Vicenza 5
Athens 4
Baghdad 4
Brno 4
Cagliari 4
Dallas 4
Edinburgh 4
Genoa 4
Haikou 4
New Bedfont 4
Ottawa 4
Taizhou 4
Toronto 4
Verona 4
Amsterdam 3
Belo Horizonte 3
Bologna 3
Borgomanero 3
Budapest 3
Ferrara di Monte Baldo 3
Fortaleza 3
Geislingen an der Steige 3
Totale 21.128
Salva come PNG Salva come JPEG
Nome #
The left atrial appendage: from embryology to prevention of thromboembolism 185
A Randomized Trial of Pharmacogenetic Warfarin Dosing in Naive Patients with Non-Valvular Atrial Fibrillation 169
'Criteria' aPL tests: Report of a Task Force and preconference workshop at the 13th International Congress on Antiphospholipid Antibodies, Galveston, Texas, April 2010 149
Antibody profile and clinical course in primary anti phospholipid syndrome with pregnancy morbidity 147
Laboratory testing for antiphospholipid syndrome 142
Plasma exchange for the management of the catastrophic antiphospholipid syndrome: importance of the type of fluid replacement. 138
A case of resistance to clopidogrel and prasugrel after percutaneous coronary angioplasty. 135
Antibodies to Domain I of β2-Glycoprotein I are in Close Relation to Patients Risk Categories in Antiphospholipid Syndrome (APS) 134
Diagnosis and therapy of antiphospholipid syndrome 134
Circulating β2 glycoprotein I-IgG anti-β2 glycoprotein I immunocomplexes in patients with definite Antiphospholipid Syndrome. 131
A comparison of a moderate with moderate-high intensity oral anticoagulant treatment in patients with mechanical heart valve prostheses 130
Antiphospholipid syndrome: interpretation of laboratory data 125
An unusual acute coronary syndrome: undisclosed disease hidden under a confounding clinical presentation 125
Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans. 124
Antiphospholipid syndrome and the heart: A case series and literature review 124
Influence of different IgG anticardiolipin antibody cut-off values on antiphospholipid syndrome classification 123
APS - Diagnostics and challenges for the future 123
Prescription of vitamin K inhibitors in low-risk patients with atrial fibrillation 122
Laboratory and clinical features of pregnant women with antiphospholipid syndrome and neonatal outcome. 121
Interpretation of laboratory data and need for reference laboratories. 121
Incidence of a first thromboembolic event in carriers of isolated lupus anticoagulant 121
Catastrophic antiphospholipid syndrome: Lessons from 14 cases successfully treated in a single center. A narrative report 121
Additional Treatments for High-Risk Obstetric Antiphospholipid Syndrome: a Comprehensive Review 120
Comparative classification of thrombotic formations on bileaflet mechanical heart valves by phonographic analysis 119
The Paradox of the Lupus Anticoagulant: History and Perspectives 118
A pharmacokinetic-pharmacodynamic model for individualisation of an oral anticoagulation therapy 116
Lupus anticoagulant testing: Diluted Russell Viper Venom Time (dRVVT) 115
The J-elongated conformation of β2-glycoprotein I predominates in solution: implications for our understanding of antiphospholipid syndrome 115
Dyspnoea in a young woman: the opposite of every truth is just as true 114
A Bridging Protocol in High-Thrombotic Risk Mechanical Valve Bearers Undergoing Surgery or Invasive Procedures 114
Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. 114
A combination therapy protocol of plasmapheresis, intravenous immunoglobulins and betamethasone to treat anti-Ro/La-related congenital atrioventricular block. A case series and review of the literature. 113
An Approach to Differential Diagnosis of Antiphospholipid Antibody Syndrome and Related Conditions 113
Antibodies to Domain 4/5 (Dm4/5) of β2-Glycoprotein 1 (β2GP1) in different antiphospholipid (aPL) antibody profiles 112
Antiphospholipid syndrome: critical analysis of the diagnostic path 111
Use of a new silica clotting time for diagnosing lupus anticoagulant in patients who meet the clinical criteria for antiphospholipid syndrome 111
ANTIPHOSPHOLIPID ANTIBODIES ARE NOT PRESENT IN THE MEMBRANE OF GEL-FILTERED PLATELETS OF PATIENTS WITH IGG ANTICARDIOLIPIN ANTIBODIES, LUPUS ANTICOAGULANT AND THROMBOSIS 110
Low molecular weight heparin (parnaparin) for cardioembolic events prevention in patients with atrial fibrillation undergoing elective electrical cardioversion: a prospective cohort study 110
Major bleeding in patients undergoing PCI and triple or dual antithrombotic therapy: a parallel-cohort study 110
Deep Venous Thrombosis After Surgery for Inflammatory Bowel Disease: Is Standard Dose Low Molecular Weight Heparin Prophylaxis Enough? 109
Immunosuppressive treatment in a heart transplantation candidate with antiphospholipid syndrome 108
The Redox Enzyme p66Shc Contributes to Diabetes and Ischemia-Induced Delay in Cutaneous Wound Healing 108
Correct laboratory approach to APS diagnosis and monitoring 108
VKORC1, CYP2C9 and CYP4F2 genetic-based algorithm for warfarin dosing: an Italian retrospective study 108
Lupus anticoagulant identifies two distinct groups of patients with different antibody patterns 108
Aspirin and recurrent venous thromboembolism in patients with symptomatic atherosclerosis: retrospective cohort study 107
Consequences of warfarin suspension after major bleeding in very elderly patients with non valvular atrial fibrillation 107
Artificial Nutrition and Hydration in Terminally Ill Patients with Advanced Dementia: Opinions and Correlates among Italian Physicians and Nurses 106
Relationship between antiphosphatidylserine/prothrombin and conventional antiphospholipid antibodies in primary antiphospholipid syndrome. 105
PURIFICATION OF ANTICARDIOLIPIN AND LUPUS ANTICOAGULANT ACTIVITIES BY USING CARDIOLIPIN IMMOBILIZED ON AGAROSE BEADS 104
Bileaflet mechanical heart valve closing sounds: in vitro classification by phonocardiographic analysis 104
Antiphospholipid syndrome: antibodies to Domain 1 of β2-glycoprotein 1 correctly classify patients at risk 104
Cancer as a risk factor for stroke in atrial fibrillation patients receiving long-term oral anticoagulant therapy 104
Antiphosphatidylserine/prothrombin antibodies in primary antiphospholipid syndrome. 104
BINDING OF AUTOIMMUNE CARDIOLIPIN-REACTIVE ANTIBODIES TO HEPARIN - A MECHANISM OF THROMBOSIS 103
A two-step coagulation test to identify antibeta-glycoprotein I lupus anticoagulants 103
Use of D-dimer testing to determine duration of anticoagulation, risk of cardiovascular events and occult cancer after a first episode of idiopathic venous thromboembolism: the extended follow-up of the PROLONG study 103
The American College of Chest Physician score to assess the risk of bleeding during anticoagulation in patients with venous thromboembolism 103
DOAC plasma levels measured by chromogenic anti-Xa assays and HPLC-UV in apixaban- and rivaroxaban-treated patients from the START-Register 103
Long-term use of vitamin K antagonists and incidence of cancer: a population-based study 102
A comparison between six- and four-week intervals in surveillance of oral anticoagulant treatment 102
A combination therapy to treat second-degree anti-ro/la-related congenital heart block. A strategy to avoid stable third-degree heart block? 102
Efficacy and safety of rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome: Rationale and design of the Trial on Rivaroxaban in AntiPhospholipid Syndrome (TRAPS) trial 102
Effectiveness and safety of oral anticoagulation with non-vitamin K antagonists compared to well-managed vitamin K antagonists in naïve patients with non-valvular atrial fibrillation: Propensity score matched cohort study 101
Effect of CYP4F2, VKORC1, and CYP2C9 in Influencing Coumarin Dose: A Single-Patient Data Meta-Analysis in More Than 15,000 Individuals 101
APS - controversies in diagnosis and management, critical overview of current guidelines 100
Mild inflammation may switch on again atrial fibrillation after successful electrical cardioversion 100
Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. 100
A simple scheme to initiate oral anticoagulant treatment in outpatients with nonrheumatic atrial fibrillation 100
Identifying novel thrombin interactions: alpha-synuclein binds to thrombin exosites and inhibits thrombin-mediated platelet aggregation 99
Confirmation of the initial antiphospholipid antibody positivity depends on antiphospholipid antibody profile 99
The association between circulating antibodies against domain I of beta2-glycoprotein I and thrombosis: an international multicenter study 98
Bidimensional immunoelectrophoresis abnormal migration of serum antithrombin III in coumarin-treated patients. 98
A comparison of lupus anticoagulant-positive patients with clinical picture of Antiphospholipid syndrome and those without 97
Antiphospholipid syndrome classification criteria: comments on the letter of Swadzba and Musial 97
Application of wavelet analysis to the phonocardiographic signal of mechanical heart valve closing sounds 97
Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome 97
Worldwide management of oral anticoagulant therapy: the ISAM study 96
Antibody profiles for the diagnosis of antiphospholipid syndrome 96
Autoimmune antiphospholipid antibodies are directed against a cryptic epitope expressed when β2-glycoprotein I is bound to a suitable surface 95
A contribution to the debate on the laboratory criteria that define the antiphospholipid syndrome 95
Anti-beta(2)-glycoprotein I ELISA assay: The influence of different antigen preparations 95
Minimizing the risk of hemorrhagic stroke during anticoagulant therapy for atrial fibrillation 95
Diagnostics and treatment of thrombotic antiphospholipid syndrome (APS): A personal perspective 95
Accelerated atherosclerosis in the aortic arch and cerebral ischemia in a patient with primary antiphospholipid syndrome 94
Phonocardiographic classification of mechanical heart valves using artificial neural networks 94
Recovery from catastrophic antiphospholipid syndrome by a plasma exchange procedure: Report of four cases and review of the literature 93
Molecular Mapping of α -Thrombin( α T)/ β 2-Glycoprotein I(β2GpI) Interaction Reveals How β2GpI Affects α T Functions 93
Comorbidities, alone and in combination with D-dimer, as risk factors for recurrence after a first episode of unprovoked venous thromboembolism in the extended follow-up of the PROLONG study 92
Family history of venous thrombosis or sudden death as a risk factor for venous thromboembolism. 92
Pharmacokinetic and pharmacodynamic re-evaluation of a genetic-guided warfarin trial 92
PAIMS-2 - ALTEPLASE COMBINED WITH HEPARIN VERSUS HEPARIN IN THE TREATMENT OF ACUTE PULMONARY-EMBOLISM - PLASMINOGEN-ACTIVATOR ITALIAN MULTICENTER STUDY-2 91
A PK-PD model for predicting the impact of age, CYP2C9, and VKORC1 genotype on individualization of warfarin therapy 91
Purification of anticardiolipin and lupus anticoagulant activities by using cardiolipin immobilized on agarose beads. 91
β2-Glycoprotein I Binds to Thrombin and Selectively Inhibits the Enzyme Procoagulant Functions 91
Fatal cerebral hemorrhage complicating thromboembolic stroke in a patient with prosthetic mitral valve thrombosis treated with thrombolytic therapy. 90
Should patients with mitral stenosis and atrial fibrillation receive combined antithrombotic therapy? 90
Patients with primary antiphospholipid antibody syndrome and without associated vascular risk factors present a normal endothelial function. 90
Assessing the relative potency of (S)- and (R)-warfarin with a new PK-PD model, in relation to VKORC1 genotypes 90
Detection of lupus anticoagulant in the era of direct oral anticoagulants 90
Totale 10.911
Salva come PNG Salva come JPEG
Categoria #
all - tutte 97.178
article - articoli 89.660
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 1.463
Totale 188.301
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.696 0 0 0 0 0 0 0 0 625 548 220 303
2020/20213.580 134 339 94 341 112 407 118 341 560 227 472 435
2021/20224.305 127 444 556 389 129 232 177 503 214 90 479 965
2022/20232.947 740 248 53 327 500 351 9 199 342 21 113 44
2023/20241.196 63 203 136 74 69 105 72 70 50 20 156 178
2024/20253.139 19 373 329 194 796 115 311 470 532 0 0 0
Totale 26.339